glp 1 agonists for type 2 diabetes GLP-1-based therapies diabetes: from single, dual and triple to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome Mapping the effectiveness and risks

This review highlights that given the robust preclinical evidence and high public interest, there is a critical need for well-designed human trials to assess the safety, efficacy, and clinical utility of BPC-157 in musculoskeletal medicine

Intranasal administration of recombinant progranulin inhibits bronchial smooth muscle hyperresponsiveness in mouse allergic asthma

Evidence Based Care

Angiogenesis (BPC-157 and TB-500) Both BPC-157 and TB-500 promote new blood vessel formation in animal models

Antioxidant enzymes/parameter SOD ( p = 0.0001, 0.0001, 0.0001), CAT ( p = 0.0001, 0.0001, 0.0001), GST ( p = 0.0001, 0.0001, 0.0001), and GSH ( p = 0.0001, 0.0001, 0.0001) were depleted, while TBARS levels increased significantly ( p = 0.0001, 0.0001, 0.0001)